Guillain-Barré syndrome after COVID-19 vaccination: report of two cases from Vietnam

Hai, Pham Dang; Phuong, Le Lan; Tot, Nguyen Hong; Anh, Nguyen Le Phuong; Tung, Nguyen Dinh; Quan, Nguyen Hong

doi:10.3855/jidc.16998

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Under this scenario, autoantibodies, induced by an external factor, target epitopes on peripheral nerves and induce axonal damage and neuronal demyelination ( 46 , 47 ). Therefore, some authors suggested that GBS following the administration of the COVID-19 adenoviral vector vaccine is due to cross-reaction between generated antibodies against SARS-CoV-2 spike protein and neuronal proteins ( 48 – 50 ). Moreover, using a bioinformatic approach the molecular mimicry was predicted between spike protein epitopes and sequences of eight proteins involved in biological processes related to myelin and axons, i.e., neural cell adhesion molecule, receptor-type tyrosine-protein phosphatase zeta, teneurin-4, receptor tyrosine-protein kinase erbB-2-, integrin alpha-X, integrin beta-1, attractin, and myelin-associated glycoprotein ( 51 ).…”

Section: Evaluating the Hypothesesmentioning

confidence: 99%

Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors

Rzymski

2023

Front. Immunol.

View full text Add to dashboard Cite

COVID-19 vaccination is a life-saving intervention. However, it does not come up without a risk of rare adverse events, which frequency varies between vaccines developed using different technological platforms. The increased risk of Guillain-Barré syndrome (GBS) has been reported for selected adenoviral vector vaccines but not for other vaccine types, including more widely used mRNA preparations. Therefore, it is unlikely that GBS results from the cross-reactivity of antibodies against the SARS-CoV-2 spike protein generated after the COVID-19 vaccination. This paper outlines two hypotheses according to which increased risk of GBS following adenoviral vaccination is due to (1) generation of anti-vector antibodies that may cross-react with proteins involved in biological processes related to myelin and axons, or (2) neuroinvasion of selected adenovirus vectors to the peripheral nervous system, infection of neurons and subsequent inflammation and neuropathies. The rationale behind these hypotheses is outlined, advocating further epidemiological and experimental research to verify them. This is particularly important given the ongoing interest in using adenoviruses in developing vaccines against various infectious diseases and cancer immunotherapeutics.

show abstract

Section: Evaluating the Hypothesesmentioning

confidence: 99%

Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors

Rzymski

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Azd-1222

2023

Reactions Weekly

View full text Add to dashboard Cite

Guillain-barre syndrome following COVID-19 vaccination: A study of 70 case reports

Sah,

Fatima,

Sah

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background and objective: Guillain-Barre Syndrome (GBS) has been found to have some interesting association with vaccinations. This paper mainly focuses on exploring different associations between COVID-19 vaccination and GBS. Methods: Electronic databases such as PubMed, Google Scholar, Cochrane, and Embase were searched using MESH terms for case reports published till 1st August 2023 from which 70 case reports were documented involving 103 individuals from 23 different countries. Result and discussion: The case reports were from a wide range of individuals aged from 13 to 87 years with an average age of 53±20 IQR years along with male predominance. The average time between receiving the vaccine and the onset of symptoms was 13.08±2.14 days. Prominent clinical features included back pain, facial diplegia, weakness, and paresthesia whereas the main diagnostic studies were cerebrospinal fluid (CSF) analysis and electromagnetic studies. The principal diagnostic clue was albumin-cytological dissociation in CSF while being negative for anti-ganglioside antibodies or SARS-CoV-2. Available treatment options consisted of IVIG and Plasmapheresis. Patients with comorbidities such as diabetes mellitus, hypertension, dyslipidemia, permanent atrial fibrillation, hypothyroidism, Hashimoto’s thyroiditis, COPD, asthma, osteoporosis, migraine, rheumatoid arthritis, osteoarthritis, ulcerative colitis, celiac disease, seizures, bipolar disorder, endometriosis, multiple sclerosis, bell’s palsy, squamous cell carcinoma, prostate cancer were included in our study. Conclusion: Overall, this review evaluated innovative and clinically relevant associations between COVID-19 vaccination and GBS. Understanding of this uncommon potential side effect of COVID-19 vaccination is crucial for prompt diagnosis and appropriate treatment. Importantly, GBS should not be considered a contraindication to vaccination. This underscores the importance of ongoing research to enhance the safety and efficacy of COVID-19 vaccination efforts.

show abstract

Guillain-Barré syndrome after COVID-19 vaccination: report of two cases from Vietnam

Cited by 5 publications

References 13 publications

Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors

Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors

Azd-1222

Guillain-barre syndrome following COVID-19 vaccination: A study of 70 case reports

Contact Info

Product

Resources

About